Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPHCDL)

• Drug Name: GLPG-0634 Drug Info
• Synonyms: Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 2	[1]
Cutaneous lupus erythematosus	EB5Z	Phase 2	[2]
Rheumatoid arthritis	FA20	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 49831257
  CAS Number: CAS 1206161-97-8
  TTD Drug ID: DMPHCDL

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 1 (JAK-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[4]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[5]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[6]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[7]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[8]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[2]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[1]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[7]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[2]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Modulator	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7913).
• [4] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [5] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
• [8] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
• [9] Clinical pipeline report, company report or official report of Aclaris Therapeutics.